Scottish-based BioOutsource Ltd., a firm focusing on biological analysis of biosimilar molecules for the biopharmaceutical industry, opened its first US facility at the Cambridge Innovation Center in Cambridge, Massachusetts. The office will be located on Kendall Square, adjacent to the Massachusetts Institute of Technology campus and home to a number of growing life sciences and venture capital firms.
“We have opened this new office, our first in the U.S., in response to increasing demand from across the North American market for our market-leading BioAnalytical services, and particularly in the field of biological biosimilar characterization,” BioOutsource CEO Gerry MacKay said. “Our U.S. office will facilitate engagement with North American customers for our off-the-shelf biosimilar biological characterization assays, for example for Humira, Enbrel, Rituxan, Herceptin, Remicade, and Avastin.”
“We are in the fortunate position to have been first-to-market in both Europe and the U.S. with our assays, and count Big Pharma as well as leading biotechnology as valued customers,” said Verna McErlane, PhD, BioOutsource Director of Sales & Business Development, BioAnalytical Division. “We look forward to being able to interact with them and provide our market-leading services, that much more readily, from our North American base of operations in Cambridge. Cambridge is, of course, part of greater Boston, which is now the number one cluster for early-stage biotechnology, and a growing center of operations for some of the world’s leading pharmaceutical firms, as well.”
“We see the North American market as an essential strategic element of our global expansion plans. We remain committed to not only growing our business in North America but in nurturing our relationships with our existing North American clients, as well. We invite all our customers and potential customers to stop by our new offices whenever you are in the Boston area,” MacKay added.